TNFSF14 and Miyoshi myopathy: The median TTP was 6.4 (IQR 5.3–8.2) years for the entire cohort, and at the end of follow up, 316 patients were treated due to progression (19 for systemic light chain amyloidosis, 192 for symptomatic MM, 105 for SLiM criteria or rapidly evolving monoclonal proteins) whereas 388 were censored.